Advanced Solid Tumors Clinical Trials in Portland, Oregon

6 studies are recruiting for advanced solid tumors in Portland, Oregon right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

   The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-428 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or other DDR deficiencies or high replication stress, and to determine the maximum tolerated dose (MTD…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Knight Cancer Institute, Portland, Oregon

   Locations

   8 in total

   Run by

   FoRx Therapeutics AG

   See if you can join NCT07356453 on ClinicalTrials.gov

2. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Providence Health & Services, Portland, Oregon

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

3. A Study of PHN-012 in Patients With Advanced Solid Tumors

   This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   PHN-012-001 Site, Portland, Oregon

   Locations

   26 in total

   Run by

   Pheon Therapeutics

   See if you can join NCT07127874 on ClinicalTrials.gov

4. A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

   Phase 1 first-in-human, open-label, dose-escalation (3 + 3), dose-expansion clinical trial to evaluate the safety, tolerability and preliminary clinical efficacy of M3T01 (fully human IgG4/kappa monoclonal antibody targeting FasL) in subjects with metastatic or unresectable solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon

   Run by

   Providence Health & Services

   See if you can join NCT06719362 on ClinicalTrials.gov

5. Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

   The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Oregon Health & Science University, Portland, Oregon

   Locations

   39 in total

   Run by

   ModernaTX, Inc.

   See if you can join NCT05533697 on ClinicalTrials.gov

6. A Clinical Study of YL205 in Patients With Advanced Solid Tumors

   This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Providence Cancer Institute - Franz Clinic, Portland, Oregon

   Locations

   43 in total

   Run by

   MediLink Therapeutics (Suzhou) Co., Ltd.

   See if you can join NCT06459973 on ClinicalTrials.gov